Tokyo Tape
Sign in
← Jmdc

Quarterly report · Q1

4483.TEDINET S100P0TK
Period2022-04-01 → 2022-06-30
Filed2022-08-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥5.8bn2022-04-01 → 2022-06-30Cons.Revenue IFRS
Revenue¥21.8bn2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥4.5bn2021-04-01 → 2021-06-30Cons.Revenue IFRS
Operating income¥1.1bn2022-04-01 → 2022-06-30Cons.Operating profit loss IFRS
Operating income¥823m2021-04-01 → 2021-06-30Cons.Operating profit loss IFRS
Profit before tax¥1.1bn2022-04-01 → 2022-06-30Cons.Profit loss before tax IFRS
Profit before tax¥4.8bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥806m2021-04-01 → 2021-06-30Cons.Profit loss before tax IFRS
Net income (owners)¥765m2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥3.2bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥538m2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income¥759m2022-04-01 → 2022-06-30Cons.Profit loss IFRS
Net income¥538m2021-04-01 → 2021-06-30Cons.Profit loss IFRS
Total assets¥63.3bnat 2022-06-30Cons.Assets IFRS
Total assets¥62.1bnat 2022-03-31Cons.Assets IFRS
Total assets¥57.3bnat 2021-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥31.9bnat 2022-06-30Cons.Liabilities IFRS
Total liabilities¥30.9bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥31.4bnat 2022-06-30Cons.Equity IFRS
Net assets / equity¥31.2bnat 2022-03-31Cons.Equity IFRS
Net assets / equity¥28.3bnat 2021-06-30Cons.Equity IFRS
Net assets / equity¥28.3bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥31.4bnat 2022-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥31.2bnat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥28.3bnat 2021-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥10.1bnat 2022-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥13.2bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥17.9bnat 2021-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥19.9bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥1.1bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥3.8bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥805m2021-04-01 → 2021-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥3.2bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥8.1bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥1.3bn2021-04-01 → 2021-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥909m2022-04-01 → 2022-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥2.4bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥1.4bn2021-04-01 → 2021-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥13.552022-04-01 → 2022-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥57.742021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥9.622021-04-01 → 2021-06-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥12.732022-04-01 → 2022-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥54.162021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥9.032021-04-01 → 2021-06-30Cons.Diluted earnings loss per share IFRS
Equity ratio49.7%at 2022-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio50.2%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio49.4%at 2021-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥58m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥58m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥90m
jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2022-04-01 → 2022-06-30¥910m
jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2022-04-01 → 2022-06-30¥869m
jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥41m
jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2022-04-01 → 2022-06-30¥47m
jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segmentrevenue2022-04-01 → 2022-06-30¥3.7bn
jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segmentrevenue external2022-04-01 → 2022-06-30¥3.7bn
jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥17m
jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segmentsegment profit2022-04-01 → 2022-06-30¥1.1bn
jpcrp040300-q1r_E35308-000Tele Medicinereportable segmentrevenue2022-04-01 → 2022-06-30¥1.2bn
jpcrp040300-q1r_E35308-000Tele Medicinereportable segmentrevenue external2022-04-01 → 2022-06-30¥1.2bn
jpcrp040300-q1r_E35308-000Tele Medicinereportable segmentsegment profit2022-04-01 → 2022-06-30¥439m
—segment totalrevenue2022-04-01 → 2022-06-30¥5.8bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥5.8bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥58m
—segment totalsegment profit2022-04-01 → 2022-06-30¥1.6bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-06-30−¥35m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-06-30−¥35m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-06-30−¥74m
jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2021-04-01 → 2021-06-30¥782m
jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2021-04-01 → 2021-06-30¥755m
jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥27m
jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2021-04-01 → 2021-06-30¥49m
jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segmentrevenue2021-04-01 → 2021-06-30¥2.8bn
jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segmentrevenue external2021-04-01 → 2021-06-30¥2.7bn
jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥8m
jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segmentsegment profit2021-04-01 → 2021-06-30¥858m
jpcrp040300-q1r_E35308-000Tele Medicinereportable segmentrevenue2021-04-01 → 2021-06-30¥1.0bn
jpcrp040300-q1r_E35308-000Tele Medicinereportable segmentrevenue external2021-04-01 → 2021-06-30¥1.0bn
jpcrp040300-q1r_E35308-000Tele Medicinereportable segmentsegment profit2021-04-01 → 2021-06-30¥330m
—segment totalrevenue2021-04-01 → 2021-06-30¥4.6bn
—segment totalrevenue external2021-04-01 → 2021-06-30¥4.5bn
—segment totalrevenue intersegment2021-04-01 → 2021-06-30¥35m
—segment totalsegment profit2021-04-01 → 2021-06-30¥1.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 683
ItemContextValueUnit
Segment profit loss IFRSPrior1YTDDuration_ReportableSegmentsMember1238000000JPY
Segment profit loss IFRSPrior1YTDDuration_ReconcilingItemsMember-74000000JPY
Segment profit loss IFRSPrior1YTDDuration1164000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q1r_E35308-000HealthcareBigDataReportableSegmentMember3731000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q1r_E35308-000TeleMedicineReportableSegmentMember1175000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q1r_E35308-000DispensingPharmacySupportReportableSegmentMember869000000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReportableSegmentsMember5776000000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSCurrentYTDDuration5776000000JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q1r_E35308-000HealthcareBigDataReportableSegmentMember17000000JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q1r_E35308-000TeleMedicineReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q1r_E35308-000DispensingPharmacySupportReportableSegmentMember41000000JPY
Intersegment revenue IFRSCurrentYTDDuration_ReportableSegmentsMember58000000JPY
Intersegment revenue IFRSCurrentYTDDuration_ReconcilingItemsMember-58000000JPY
Intersegment revenue IFRSCurrentYTDDuration－JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q1r_E35308-000HealthcareBigDataReportableSegmentMember3749000000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q1r_E35308-000TeleMedicineReportableSegmentMember1175000000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q1r_E35308-000DispensingPharmacySupportReportableSegmentMember910000000JPY
Revenue IFRSCurrentYTDDuration_ReportableSegmentsMember5835000000JPY
Revenue IFRSCurrentYTDDuration_ReconcilingItemsMember-58000000JPY
Revenue IFRSCurrentYTDDuration5776000000JPY
Segment profit loss IFRSCurrentYTDDuration_jpcrp040300-q1r_E35308-000HealthcareBigDataReportableSegmentMember1124000000JPY
Segment profit loss IFRSCurrentYTDDuration_jpcrp040300-q1r_E35308-000TeleMedicineReportableSegmentMember439000000JPY
Segment profit loss IFRSCurrentYTDDuration_jpcrp040300-q1r_E35308-000DispensingPharmacySupportReportableSegmentMember47000000JPY
Segment profit loss IFRSCurrentYTDDuration_ReportableSegmentsMember1611000000JPY
Segment profit loss IFRSCurrentYTDDuration_ReconcilingItemsMember-90000000JPY
Segment profit loss IFRSCurrentYTDDuration1521000000JPY
Segment profit loss IFRSPrior1YTDDuration1164000000JPY
Segment profit loss IFRSCurrentYTDDuration1521000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration365000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration444000000JPY
Other income IFRSPrior1YTDDuration25000000JPY
Other income IFRSCurrentYTDDuration19000000JPY
Other expenses IFRSPrior1YTDDuration0JPY
Other expenses IFRSCurrentYTDDuration14000000JPY
Operating profit loss IFRSPrior1YTDDuration823000000JPY
Operating profit loss IFRSCurrentYTDDuration1081000000JPY
Finance income IFRSPrior1YTDDuration0JPY
Finance income IFRSCurrentYTDDuration54000000JPY
Finance costs IFRSPrior1YTDDuration16000000JPY
Finance costs IFRSCurrentYTDDuration16000000JPY
Profit loss before tax IFRSPrior1YTDDuration806000000JPY
Profit loss before tax IFRSCurrentYTDDuration1120000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2022-08-12
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第10期第１四半期（自　2022年４月１日　至　2022年６月30日）
Company name cover pageFilingDateInstant
Original text (Japanese)株式会社ＪＭＤＣ
Company name in english cover pageFilingDateInstantJMDC Inc.

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-06-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass